In the pharmaceutical and biotechnology industries, the Director-to-VP transition is the single most contested career advancement in the organizational hierarchy. Our placement data across pharma and biotech clients over the past five years reveals a consistent pattern: the ratio of Directors to VPs at major pharmaceutical companies averages approximately 4:1, meaning that for every VP seat that opens, there are four qualified Directors competing for it. At the largest pharma companies — the Pfizers, Roches, and Novartises — the ratio can approach 6:1 in functions like Clinical Development and Regulatory Affairs where the Director title is the standard operating-level leadership position.
This structural bottleneck is not unique to pharma, but the specific factors that determine who breaks through and who doesn’t are deeply industry-specific. In life sciences, the Director-to-VP transition is shaped by therapeutic area expertise, regulatory knowledge, publication records, cross-functional visibility, and a set of organizational dynamics that differ materially from the technology or financial services sectors where we also place senior professionals. This piece examines what separates Directors who advance from those who plateau, based on our direct observation of several hundred pharma and biotech careers.
What differentiates those who advance
From tracking the careers of Directors who successfully made VP in pharma and biotech, five characteristics appear consistently among those who break through. These are not soft attributes like "executive presence" — they are specific, demonstrable capabilities that hiring committees and promotion boards evaluate explicitly.
Program-level P&L accountability. Directors who have owned the budget and timeline for a clinical program or product launch — not just managed execution within it — have a fundamentally different credential than those whose scope is limited to functional execution. The VP role in pharma typically involves managing across multiple programs or functions, and the most credible evidence of readiness is having already done so at the program level, even without the VP title.
Regulatory fluency beyond your function. The Directors who advance fastest are those who understand the regulatory landscape beyond their immediate functional area. A Director of Clinical Operations who can speak credibly about CMC timelines, regulatory submission strategy, and commercial launch sequencing is demonstrating the cross-functional perspective that VP roles require. This regulatory fluency is the life sciences equivalent of "business acumen" in other industries, and it is developed through deliberate cross-functional engagement rather than through tenure alone.
External visibility in the scientific community. Unlike most corporate career tracks, pharma and biotech career advancement is influenced by the candidate’s reputation outside the company. Directors who are known to KOLs in their therapeutic area, who present at major medical conferences, and who are sought out by CROs and academic collaborators for their expertise carry a form of professional currency that internal-only Directors cannot match. This external visibility signals to promotion committees that the candidate has a reputation worth investing in.
Cross-functional visibility
Cross-functional visibility in pharma is not the generic "networking" advice that applies in any industry. It has specific, structural dimensions tied to how drug development programs are organized. The most consequential cross-functional relationships for a Director seeking VP advancement are with the functions that will be their peers at the VP level: Clinical Development, Regulatory Affairs, Commercial, Medical Affairs, and CMC/Manufacturing.
The practical mechanism for building this visibility is participation in cross-functional governance bodies: Joint Development Committees, Portfolio Review Committees, Launch Excellence Teams, and the cross-functional teams that prepare for FDA advisory committee meetings. Directors who are selected for these bodies — and who contribute substantively rather than passively attending — build the reputation with VP-level peers that creates advocacy for their promotion. A VP of Regulatory Affairs who has worked with you on two FDA advisory committee preparations and considers you a strong cross-functional partner is a more effective advocate for your VP promotion than a decade of performance reviews.
The mistake many Directors make is treating cross-functional work as a distraction from their "real" functional responsibilities. In pharma, the cross-functional work is the VP job. A VP of Clinical Operations who cannot work effectively with Regulatory, Commercial, and Medical Affairs is failing at the core requirement of the role. Directors who demonstrate this capability before promotion are providing the strongest possible evidence that they are ready for it.
Therapeutic area breadth vs. depth
One of the most consequential career decisions for a Director in pharma is whether to build deep expertise in a single therapeutic area or develop breadth across multiple areas. The answer depends on the career path being pursued and the type of company being targeted.
Deep therapeutic area expertise — 10+ years in oncology, or CNS, or immunology — creates a distinct competitive advantage for VP roles at companies with concentrated portfolios. A biotech focused exclusively on solid tumor oncology wants a VP of Clinical Development who has lived and breathed that therapeutic area for a career, who knows the KOLs, who understands the competitive landscape, and who can evaluate clinical data with deep domain intuition. For these roles, breadth is a liability — it signals that the candidate may not have the depth required to make the judgment calls that the role demands.
Therapeutic area breadth — experience across oncology, immunology, and rare disease, for example — creates a different advantage for VP roles at diversified pharma companies or platform biotechs that are pursuing multiple therapeutic approaches. These companies need VPs who can evaluate programs across areas and make portfolio-level tradeoffs, which requires the ability to apply clinical judgment beyond a single therapeutic domain. For these roles, depth in a single area without breadth signals a potential limitation in portfolio thinking.
The practical guidance: Directors at large pharma companies should develop at least secondary therapeutic area exposure by seeking cross-functional assignments or internal rotations, even while maintaining a primary area of depth. Directors at focused biotechs should double down on their therapeutic area expertise while ensuring they develop the cross-functional breadth that VP roles require. The worst outcome is being neither deep enough for focused companies nor broad enough for diversified ones.
The publication trap
There is a specific career trap in pharma and biotech that we call the "publication trap," and it catches a meaningful number of talented Directors. The trap works like this: a Director with a strong scientific background invests heavily in publishing peer-reviewed papers and presenting at medical conferences, believing that a robust publication record will differentiate them for VP promotion. The publication record grows. Conference presentations multiply. The Director becomes well-known in their therapeutic area’s academic community. And the VP promotion doesn’t come.
The reason is structural: publication and conference activity, while valued, is not what pharma companies optimize for in VP-level leadership. The VP role requires operational leadership, team management, budget accountability, and the ability to make decisions under uncertainty with incomplete information. A Director who has spent the marginal hours of their career writing papers rather than managing cross-functional programs, building organizational capability, or taking on stretch operational assignments has optimized for the wrong output. The publication record demonstrates scientific credibility, which is necessary but not sufficient for VP advancement. What’s missing is evidence of operational leadership at scale.
This is not to say that publications are irrelevant — they contribute to the external visibility that matters for VP candidacy. But they should be a byproduct of program leadership, not a substitute for it. The Director who publishes the results of a program they led from IND to Phase 2 data readout has both the operational credential and the publication. The Director who publishes review articles and opinion pieces while someone else runs the programs has only the publication.
Making the move: internal vs. external
Approximately 55% of Director-to-VP transitions in our pharma and biotech placement data occur through external moves rather than internal promotion. This is a higher external-move rate than in most industries and reflects two pharma-specific dynamics: the 4:1 ratio creates intense internal competition that external markets can bypass, and the biotech ecosystem’s continuous formation of new companies creates VP-level opportunities that don’t exist at the Director’s current employer.
The external move path is particularly effective for Directors at large pharma companies who are competing against multiple well-qualified internal peers for a small number of VP slots. Moving to a clinical-stage biotech as VP of their function often provides not only the title advancement but a broader scope of responsibility (one VP over an entire function vs. one of several VPs in a large pharma division) and meaningful equity participation that the large pharma career path cannot match.
The risk of the external move is real and worth acknowledging: a VP title at a 50-person biotech does not carry the same organizational weight as a VP title at Pfizer or Roche, and Directors who make this move should be deliberate about choosing companies with credible science, adequate funding, and leadership teams that will provide genuine development opportunities. A VP title at a biotech that fails within 18 months can set a career back rather than advancing it.
Final thoughts
The Director-to-VP transition in pharma and biotech is navigable, but it requires deliberate strategy rather than patient tenure. The Directors who break through are those who have built cross-functional credibility, developed a reputation outside their company, taken on program-level accountability, and made the conscious decision about whether to pursue the internal or external path. The 4:1 ratio ensures that not every qualified Director will advance within their current organization, but the broader life sciences ecosystem creates enough VP-level opportunities that a well-positioned Director with a clear strategy can find the right path forward.
For additional context on compensation at the VP level in pharma and biotech, see our regulatory counsel compensation report. For guidance on negotiating equity at pre-IPO biotechs, see our equity vesting guide.